PPHVanEck Pharmaceutical ETF

Grow my money14y track recordRanked #408 of 3,055 in this goal

Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.

By VanEck · Launched 2011

Annual Cost

0.36%

#1,830 of 6,040 · low cost

Fund Size

$1.0B

#1,168 of 6,040 · large

Return (1Y)

+29.0%

Track Record

14 years

#944 of 6,040 · established

Performance

Total-return NAV · USD

Growth of $10,000

$12,708+27.1%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Pharmaceuticals

Index tracked

MVIS US Listed Pharmaceutical 25 Index

Holdings

By weight

Concentration

Top 10 holdings = 71.8% of fundconcentrated

Eli Lilly & Co

18.7%

Novartis AG

10.8%

Merck & Co Inc

9.7%

Pfizer Inc

5.2%

Novo Nordisk A/S

4.8%

Sanofi SA

4.7%

Bristol-Myers Squibb Co

4.6%

GSK PLC

4.6%

AstraZeneca PLC

4.4%

Johnson & Johnson

4.3%

Asset allocation

Stocks

100.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

18.7%Moderate

Year-on-year price swings

Max drawdown

-29.7%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

0.60Decent risk-adjusted returns

Sortino (3Y)

0.87Moderate downside risk

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.
Strategy: Uses a passive investment approach to replicate the Pharmaceutical Index by investing at least 80% of total assets in common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry, including medium-cap companies. Concentrates investments in the pharmaceutical sector to match the index's composition.
Inception date: December 20, 2011
Fund family: VanEck